Amgen has announced it is building a ‘next-generation’ biomanufacturing plant at its West Greenwich campus in Rhode Island.
The first of its kind in the US, the plant will be used to manufacture products for local and international markets and will feature various innovative technologies.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Amgen claims that it will be built in half time of a standard plant and will have half the operating costs. This is due to next-generation plants having smaller manufacturing footprints and better environmental benefits such as minimised water and energy consumption and low carbon emissions.
The plant is set to create around 150 manufacturing jobs and about 200 construction and validation jobs.
Amgen Operations executive vice-president Esteban Santos said: “Amgen has three decades of experience in biologics manufacturing, and we are proud of our track record of providing a reliable supply of high-quality medicines for patients around the world.
“We are pleased to build the first commercial scale, next-generation biomanufacturing plant in the US, leveraging Amgen’s capabilities and incorporating the latest technologies.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAmgen opened its first next-generation biomanufacturing plant in Singapore in 2014.
The company intends to use such production facilities to enable a reliable, fast and flexible increase in manufacturing capabilities and productivity.
The equipment used in the plant is portable, small and disposable, allowing more flexibility and speed when manufacturing multiple medicines.
This smaller footprint means Amgen can quickly respond to changing demands, improving the time taken for medicines to reach patients.
